Weight loss drugs linked to lower TB risk
Two recent studies have revealed that weight-loss medications such as "Ozempic" and "Mounjaro" may offer additional benefits beyond treating diabetes and obesity. Their use has been linked to a decreased risk of certain serious infectious diseases, especially tuberculosis. The studies showed that users of GLP-1 medications like "Semaglutide" and "Tirzepatide" were less likely to be diagnosed with tuberculosis or suffer from infections requiring hospitalization compared to non-users, with a noticeable reduction in infection risk over a follow-up period of five years. These findings are partly attributed to improved metabolic health and weight loss associated with these drugs, although researchers caution that the results are based on observational data and further studies are needed to confirm their protective effect against infections.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading